CN1856327A - Vegf受体抑制剂与化疗剂的组合 - Google Patents

Vegf受体抑制剂与化疗剂的组合 Download PDF

Info

Publication number
CN1856327A
CN1856327A CNA2004800275441A CN200480027544A CN1856327A CN 1856327 A CN1856327 A CN 1856327A CN A2004800275441 A CNA2004800275441 A CN A2004800275441A CN 200480027544 A CN200480027544 A CN 200480027544A CN 1856327 A CN1856327 A CN 1856327A
Authority
CN
China
Prior art keywords
inhibitor
group
independently
amino
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800275441A
Other languages
English (en)
Chinese (zh)
Inventor
G·博尔德
J·B·步吕根
J·M－J·黄
F·R·小金德
H·莱恩
E·J·拉图尔
P·W·曼利
J·M·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1856327A publication Critical patent/CN1856327A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2004800275441A 2003-09-23 2004-09-23 Vegf受体抑制剂与化疗剂的组合 Pending CN1856327A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50525003P 2003-09-23 2003-09-23
US60/505,250 2003-09-23

Publications (1)

Publication Number Publication Date
CN1856327A true CN1856327A (zh) 2006-11-01

Family

ID=34375569

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800275441A Pending CN1856327A (zh) 2003-09-23 2004-09-23 Vegf受体抑制剂与化疗剂的组合

Country Status (16)

Country Link
US (1) US20080085902A1 (https=)
EP (1) EP1682181A2 (https=)
JP (1) JP2007505938A (https=)
KR (1) KR20060097000A (https=)
CN (1) CN1856327A (https=)
AU (1) AU2004273615B2 (https=)
BR (1) BRPI0414698A (https=)
CA (1) CA2537991A1 (https=)
CO (1) CO5680459A2 (https=)
CR (1) CR8283A (https=)
EA (1) EA200600495A1 (https=)
EC (1) ECSP066437A (https=)
IL (1) IL174214A0 (https=)
MX (1) MXPA06003163A (https=)
NO (1) NO20061777L (https=)
WO (1) WO2005027972A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655863A (zh) * 2009-09-30 2012-09-05 株式会社资生堂 乙酰肝素酶活性抑制剂
WO2025160930A1 (zh) * 2024-02-02 2025-08-07 基亚生物科技股份有限公司 母帕司汀(Muparfostat)治疗胰腺癌的用途

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DE202004021759U1 (de) * 2003-02-21 2010-10-07 ResMed Ltd., Bella Vista Nasale Anordnung
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
US8029815B2 (en) 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
WO2005117553A2 (en) 2004-05-27 2005-12-15 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
WO2006035203A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib
WO2006055760A1 (en) 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
SG160364A1 (en) * 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
AU2006306240A1 (en) * 2005-10-24 2007-05-03 Novartis Ag Combination of histone deacetylase inhibitors and radiation
CN101316590B (zh) * 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
CN100441222C (zh) * 2005-12-09 2008-12-10 中国科学院广州生物医药与健康研究院 化合物ps-341在制备治疗急性髓性白血病药物中的应用
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
EP2086930A2 (en) 2006-06-12 2009-08-12 Novartis AG Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
EP2030615A3 (en) 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
WO2009036066A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
EP2393513B1 (en) * 2009-02-06 2016-10-19 The General Hospital Corporation Methods of treating vascular lesions
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CN102711756A (zh) 2010-01-14 2012-10-03 株式会社三和化学研究所 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
WO2012105610A1 (ja) 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
AU2013343425A1 (en) * 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EA201790189A1 (ru) * 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
BR102014023144B1 (pt) * 2014-09-18 2020-12-15 Universidade De São Paulo - Usp peptídeos sintéticos ligantes de receptores de vegf e seus usos
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR102371269B1 (ko) * 2020-03-11 2022-03-07 연세대학교 산학협력단 VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002066479A1 (en) * 2001-02-23 2002-08-29 Banyu Pharmaceutical Co.,Ltd. Novel isoindole derivatives
DE60231068D1 (de) * 2001-09-12 2009-03-19 Novartis Ag Die Verwendung von 4-Pyridylmethylphthalazinen zur Behandlung von Nierentumoren
IL161462A0 (en) * 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655863A (zh) * 2009-09-30 2012-09-05 株式会社资生堂 乙酰肝素酶活性抑制剂
CN102655863B (zh) * 2009-09-30 2013-11-20 株式会社资生堂 乙酰肝素酶活性抑制剂
WO2025160930A1 (zh) * 2024-02-02 2025-08-07 基亚生物科技股份有限公司 母帕司汀(Muparfostat)治疗胰腺癌的用途

Also Published As

Publication number Publication date
WO2005027972A3 (en) 2005-11-03
WO2005027972A2 (en) 2005-03-31
MXPA06003163A (es) 2006-06-05
JP2007505938A (ja) 2007-03-15
KR20060097000A (ko) 2006-09-13
NO20061777L (no) 2006-06-23
AU2004273615A1 (en) 2005-03-31
EP1682181A2 (en) 2006-07-26
IL174214A0 (en) 2006-08-01
CA2537991A1 (en) 2005-03-31
BRPI0414698A (pt) 2006-11-28
ECSP066437A (es) 2006-09-18
CO5680459A2 (es) 2006-09-29
CR8283A (es) 2006-10-10
AU2004273615B2 (en) 2009-01-15
EA200600495A1 (ru) 2006-10-27
US20080085902A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
CN1856327A (zh) Vegf受体抑制剂与化疗剂的组合
CN1165536C (zh) 与六元杂环稠合的取代的吡唑衍生物
CN1152031C (zh) 具有血管生成抑制活性的异喹啉衍生物
CN1791396A (zh) 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
CN1419452A (zh) 协同治疗癌症的方法和组合物
CN1838959A (zh) Erbb2抗癌剂的给药方案
CN1909908A (zh) 用于治疗蛋白激酶依赖性疾病的吡唑并[1,5－a]嘧啶－7－基－胺衍生物
CN101039673A (zh) 用于治疗涉及细胞增殖的疾病的组合
CN1780627A (zh) 用于治疗涉及细胞增殖、骨髓瘤细胞迁移或凋亡或者血管增殖疾病的联用药物
CN1898209A (zh) 葡糖激酶调节剂吡啶羧酸衍生物
CN1917882A (zh) 非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
TW201032806A (en) Hsp90 inhibitor combinations
CN101031551A (zh) 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂
CN1660840A (zh) 治疗炎性疾病的酞嗪衍生物
CN1662537A (zh) 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
CN1251097A (zh) 具有血管生成抑制活性的酞嗪类化合物
CN1431902A (zh) 抗高血压剂与抗血管生成剂的治疗组合物
CN1215338A (zh) 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
CN1711094A (zh) Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品
CN1520314A (zh) 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物
CN1856326A (zh) Vegf受体抑制剂与其它治疗剂的组合
CN1784232A (zh) 包含抗血管生成剂和Src抑制剂的联合的治疗药物及其治疗用途
CN1882342A (zh) Chk1抑制剂在控制细胞增殖中的应用
JP2013035853A (ja) 増殖性疾患の処置または予防のためのピリミジルアミノベンズアミド化合物とイマチニブの組み合わせ
JP2013224304A (ja) ａ）ピリミジルアミノベンズアミド化合物、およびｂ）Ｔｈｒ３１５Ｉｌｅキナーゼ阻害剤を含む、組合せ剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20061101